The University of Chicago Header Logo

Christine Bestvina

TitleAssistant Professor
InstitutionUniversity of Chicago
DepartmentMedicine-Hematology and Oncology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of Pennsylvania , Philadelphia MD05/2012
    Duke Medical Center, Durham, MD 06/2015Internal Medicine - Residency
    University of Chicago, Chicago, IL06/2018Oncology Fellowship

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Bestvina CM, Waters D, Morrison L, Emond B, Lafeuille MH, Hilts A, Lefebvre P, He A, Vanderpoel J. Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer. J Med Econ. 2024 Jan-Dec; 27(1):292-303. PMID: 38391239.
      Citations: 1     Fields:    Translation:Humans
    2. Lynch C, Korpics MC, Katipally RR, Wu T, Bestvina CM, Pitroda S, Chmura SJ, Juloori A. Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials. Int J Radiat Oncol Biol Phys. 2024 Apr 01; 118(5):1519-1530. PMID: 38199382.
      Citations:    Fields:    Translation:Humans
    3. Kuboki Y, Fakih M, Strickler J, Yaeger R, Masuishi T, Kim EJ, Bestvina CM, Kopetz S, Falchook GS, Langer C, Krauss J, Puri S, Cardona P, Chan E, Varrieur T, Mukundan L, Anderson A, Tran Q, Hong DS. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan; 30(1):265-270. PMID: 38177853.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    4. Beckermann KE, Bestvina CM, El Osta B, Sanborn RE, Borghaei H, Lammers PE, Selvaggi G, Whisenant JG, Heimann-Nichols E, Berry L, Hsu CY, Shyr Y, Horn L, Wakelee H. A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors. JTO Clin Res Rep. 2024 Feb; 5(2):100619. PMID: 38328473; PMCID: PMC10847019.
    5. Burns L, Hsu CY, Whisenant JG, Marmarelis ME, Presley CJ, Reckamp KL, Khan H, Jo Fidler M, Bestvina CM, Brahmer J, Puri S, Patel JD, Halmos B, Hirsch FR, Liu SV, Costa DB, Goldberg SB, Feldman LE, Mamdani H, Puc M, Mansfield AS, Islam N, Scilla KA, Garassino MC, Horn L, Peters S, Wakelee HA, Charlot M, Tapan U. Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT). Lung Cancer. 2023 12; 186:107423. PMID: 37995456.
      Citations:    Fields:    Translation:Humans
    6. Cameron RB, Hines JB, Torri V, Porcu L, Donington J, Bestvina CM, Vokes E, Dolezal JM, Esposito A, Garassino MC. What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer? Ther Adv Med Oncol. 2023; 15:17588359231198446. PMID: 37720499; PMCID: PMC10504845.
    7. Aldea M, Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023 07 07; 13(7):1556-1571. PMID: 37068173.
      Citations: 16     Fields:    Translation:Humans
    8. Stahlbaum D, Jablonski R, Strek ME, Bestvina CM, Polley MY, Reid P. Abnormalities on baseline chest imaging are risk factors for immune checkpoint inhibitor associated pneumonitis. Respir Med. 2023 Oct; 217:107330. PMID: 37385460.
      Citations:    Fields:    
    9. Bestvina CM, Garassino MC, Neal JW, Wakelee HA, Diehn M, Vokes EE. Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal. J Clin Oncol. 2023 09 01; 41(25):4093-4096. PMID: 37352477.
      Citations: 3     Fields:    Translation:Humans
    10. Feldt SL, Bestvina CM. The Role of MET in Resistance to EGFR Inhibition in NSCLC: A Review of Mechanisms and Treatment Implications. Cancers (Basel). 2023 May 31; 15(11). PMID: 37296959; PMCID: PMC10251884.
      Citations: 1     
    11. Hines JB, Bowar B, Levine E, Esposito A, Garassino MC, Bestvina CM. Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer. Int J Mol Sci. 2023 May 29; 24(11). PMID: 37298380; PMCID: PMC10253830.
      Citations: 2     Fields:    Translation:Humans
    12. Iams WT, Balbach ML, Phillips S, Sacher A, Bestvina C, Velcheti V, Wang X, Marmarelis ME, Sethakorn N, Leal T, Sackstein PE, Kim C, Robinson MA, Mehta K, Hsu R, Nieva J, Patil T, Camidge DR. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer. Clin Lung Cancer. 2023 05; 24(3):228-234. PMID: 36841727; PMCID: PMC10234144.
      Citations:    Fields:    Translation:Humans
    13. Kalchiem-Dekel O, Bestvina CM, Gainor JF, Drilon A, Lin JJ. Response to Provenzano et al. and De Carlo et al. J Thorac Oncol. 2023 Feb; 18(2):e13-e14. PMID: 36682841.
      Citations:    Fields:    
    14. Tran MC, Strohbehn GW, Karrison TG, Rouhani SJ, Segal JP, Shergill A, Hoffman PC, Patel JD, Garassino MC, Vokes EE, Bestvina CM. Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression. Clin Lung Cancer. 2023 05; 24(3):e117-e121. PMID: 36806414.
      Citations: 3     Fields:    Translation:Humans
    15. Katipally RR, Spurr LF, Gutiontov SI, Turchan WT, Connell P, Juloori A, Malik R, Binkley MS, Jiang AL, Rouhani SJ, Chervin CS, Wanjari P, Segal JP, Ng V, Loo BW, Gomez DR, Bestvina CM, Vokes EE, Ferguson MK, Donington JS, Diehn M, Pitroda SP. STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2023 01; 7:e2200273. PMID: 36603171; PMCID: PMC10530422.
      Citations: 1     Fields:    Translation:Humans
    16. Carneiro BA, Papadopoulos KP, Strickler JH, Lassman AB, Waqar SN, Chae YK, Patel JD, Shacham-Shmueli E, Kelly K, Khasraw M, Bestvina CM, Merrell R, Huang K, Atluri H, Ansell P, Li R, Jin J, Anderson MG, Reilly EB, Morrison-Thiele G, Patel K, Robinson RR, Aristide MRN, Gan HK. Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdac183. PMID: 36814898; PMCID: PMC9940695.
      Citations: 1     
    17. Spurr LF, Martinez CA, Kang W, Chen M, Zha Y, Hseu R, Gutiontov SI, Turchan WT, Lynch CM, Pointer KB, Chang P, Murgu S, Husain AN, Cody B, Vokes EE, Bestvina CM, Patel JD, Diehn M, Gajewski TF, Weichselbaum RR, Chmura SJ, Pitroda SP. Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022 Nov 28. PMID: 36443406.
      Citations: 14     Fields:    
    18. Rouhani SJ, Bestvina CM. Immunotherapy partners after progression: Right place, right time? Cancer. 2023 01 15; 129(2):181-183. PMID: 36420775.
      Citations:    Fields:    Translation:Humans
    19. Michaels E, Bestvina CM. Meeting an un-MET need: Targeting MET in non-small cell lung cancer. Front Oncol. 2022; 12:1004198. PMID: 36338701; PMCID: PMC9634070.
      Citations: 3     
    20. Kalchiem-Dekel O, Falcon CJ, Bestvina CM, Liu D, Kaplanis LA, Wilhelm C, Eichholz J, Harada G, Wirth LJ, Digumarthy SR, Lee RP, Kadosh D, Mendelsohn RB, Donington J, Gainor JF, Drilon A, Lin JJ. Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy. J Thorac Oncol. 2022 09; 17(9):1130-1136. PMID: 35788405; PMCID: PMC9427698.
      Citations: 9     Fields:    Translation:Humans
    21. Korpics MC, Katipally RR, Partouche J, Cutright D, Pointer KB, Bestvina CM, Luke JJ, Pitroda SP, Dignam JJ, Chmura SJ, Juloori A. Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):645-654. PMID: 35753553.
      Citations: 5     Fields:    Translation:Humans
    22. Rouhani SJ, Yu J, Olson D, Zha Y, Pezeshk A, Cabanov A, Pyzer AR, Trujillo J, Derman BA, O'Donnell P, Jakubowiak A, Kindler HL, Bestvina C, Gajewski TF. Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer. 2022 06; 10(6). PMID: 35732350; PMCID: PMC9226983.
      Citations: 6     Fields:    Translation:HumansCellsPHPublic Health
    23. Bestvina CM, Whisenant JG, Torri V, Cortellini A, Wakelee H, Peters S, Roca E, De Toma A, Hirsch FR, Mamdani H, Halmos B, Arrieta O, Metivier AC, Fidler MJ, Rogado J, Presley CJ, Mascaux C, Genova C, Blaquier JB, Addeo A, Finocchiaro G, Khan H, Morgillo F, Bar J, Aujayeb A, Mountzios G, Scotti V, Grosso F, Geraedts E, Zhumagaliyeva AN, Horn L, Garassino MC, Baena J, TERAVOLT study group, Mazieres J. Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis. JTO Clin Res Rep. 2022 Aug; 3(8):100335. PMID: 35619644; PMCID: PMC9119707.
      Citations: 8     
    24. Schild SE, Wang X, Bestvina CM, Williams T, Masters G, Singh AK, Stinchcombe TE, Salama JK, Wolf S, Zemla T, Duma N, Chun SG, Amini A, Kozono D, Watt C. Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer. Clin Lung Cancer. 2022 07; 23(5):e317-e320. PMID: 35613998; PMCID: PMC9634857.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    25. Le X, Sakai H, Felip E, Veillon R, Garassino MC, Raskin J, Cortot AB, Mazieres J, Smit EF, Thomas M, Iams WT, Cho BC, Kim HR, Yang JC, Chen YM, Patel JD, Bestvina CM, Park K, Griesinger F, Johnson M, Gottfried M, Britschgi C, Heymach J, Sikoglu E, Berghoff K, Schumacher KM, Bruns R, Otto G, Paik PK, Viteri S. Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clin Cancer Res. 2022 03 15; 28(6):1117-1126. PMID: 34789481; PMCID: PMC9365370.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    26. Whisenant JG, Baena J, Cortellini A, Huang LC, Lo Russo G, Porcu L, Wong SK, Bestvina CM, Hellmann MD, Roca E, Rizvi H, Rogado J, Pasello G, Leighl NB, Aujayeb A, Batra U, Azzam AY, Unk M, Azab MA, Zhumagaliyeva AN, Gomez-Martin C, Geraedts E, Mountzios G, Serrano-Montero G, Reinmuth N, Coate L, Marmarelis M, Presley CJ, Hirsch FR, Khan H, Baggi A, Halmos B, Ceresoli GL, Fidler MJ, Scotti V, Felip E, Tapan U, Brahmer J, Puri S, Popat S, Reckamp KL, Nadal E, Mazzoni F, Agustoni F, Bar J, Grosso F, Patel JD, Gomes F, Ibrahim E, Trama A, Bettini AC, Dingemans AM, Wakelee H, Peters S, Horn L, Garassino MC, Torri V, TERAVOLT study group, Monnet I, Boudjemaa A, Arrieta O, Blaquier JB, Garrido P, Mascaux C, Métivier AC, Falchero L, Genova C, Mazieres J, Bria E, Morgillo F, Avrillon V, Barlesi F. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. J Thorac Oncol. 2022 05; 17(5):661-674. PMID: 35121086; PMCID: PMC8804493.
      Citations: 5     Fields:    Translation:HumansCells
    27. Korpics MC, Katipally RR, Partouche J, Cutright D, Pointer KB, Bestvina CM, Luke J, Pitroda SP, Chmura SJ, Juloori A. Prospective Evaluation of Stereotactic Body Radiotherapy and Immunotherapy for Mediastinal and Hilar Lymph Node Metastases. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):S10. PMID: 34700387.
    28. Pointer KB, Katipally RR, Bestvina CM, Juloori A, Partouche J, Patel JD, Pitroda SP, Vokes EE, Weichselbaum RR, Chmura SJ. Evaluation of Initial Metastatic Tumor Location and Radiation Response to Determine Outcomes in Patients Who Received Combination Stereotactic Body Radiotherapy and Immunotherapy for NSCLC. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):e449. PMID: 34701479.
    29. Katipally RR, Korpics MC, Partouche J, Cutright D, Pointer KB, Bestvina CM, Luke JJ, Pitroda SP, Chmura SJ, Juloori A. Stereotactic Body Radiation Therapy and Immunotherapy in Abdominal and Pelvic Lymph Node Metastases. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):S58. PMID: 34700587.
    30. Gutiontov SI, Turchan WT, Spurr LF, Rouhani SJ, Chervin CS, Steinhardt G, Lager AM, Wanjari P, Malik R, Connell PP, Chmura SJ, Juloori A, Hoffman PC, Ferguson MK, Donington JS, Patel JD, Vokes EE, Weichselbaum RR, Bestvina CM, Segal JP, Pitroda SP. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059. PMID: 34625620; PMCID: PMC8501138.
      Citations: 41     Fields:    Translation:Humans
    31. Bestvina CM, Pointer KB, Karrison T, Al-Hallaq H, Hoffman PC, Jelinek MJ, Juloori A, Melotek JM, Murgu S, Partouche J, Vokes EE, Weichselbaum RR, Pitroda SP, Patel JD, Chmura SJ. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140. PMID: 34500113.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    32. Yun NK, Rouhani SJ, Bestvina CM, Ritz EM, Gilmore BA, Tarhoni I, Borgia JA, Batus M, Bonomi PD, Fidler MJ. Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy. Cancers (Basel). 2021 Mar 20; 13(6). PMID: 33804721; PMCID: PMC8003851.
      Citations: 13     
    33. Passaro A, Bestvina C, Velez Velez M, Garassino MC, Garon E, Peters S. Severity of COVID-19 in patients with lung cancer: evidence and challenges. J Immunother Cancer. 2021 03; 9(3). PMID: 33737345; PMCID: PMC7978268.
      Citations: 50     Fields:    Translation:HumansCells
    34. Serritella AV, Bestvina CM. Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer. Thorac Surg Clin. 2020 May; 30(2):137-146. PMID: 32327172.
      Citations: 4     Fields:    Translation:Humans
    35. Bestvina CM, Wroblewski KE, Daly B, Beach B, Chow S, Hantel A, Malec M, Huber MT, Polite BN. A Rules-Based Algorithm to Prioritize Poor Prognosis Cancer Patients in Need of Advance Care Planning. J Palliat Med. 2018 06; 21(6):846-849. PMID: 29649399.
      Citations: 3     Fields:    Translation:Humans
    36. Bestvina CM, Vokes EE. ALK and ROS1 rearrangement in NSCLC: rapidly evolving standards. Lancet Oncol. 2017 12; 18(12):1555-1556. PMID: 29074100.
      Citations:    Fields:    Translation:Humans
    37. Bestvina CM, Polite BN. Implementation of Advance Care Planning in Oncology: A Review of the Literature. J Oncol Pract. 2017 10; 13(10):657-662. PMID: 28586259.
      Citations: 27     Fields:    Translation:Humans
    38. Bestvina CM, Fleming GF. Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings. Oncologist. 2016 10; 21(10):1250-1259. PMID: 27412393; PMCID: PMC5061541.
      Citations: 52     Fields:    Translation:Humans
    39. Bestvina CM, Zullig LL, Yousuf Zafar S. The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature. Future Oncol. 2014 Nov; 10(14):2189-99. PMID: 25471033.
      Citations: 29     Fields:    Translation:Humans
    40. Bestvina CM, Zullig LL, Rushing C, Chino F, Samsa GP, Altomare I, Tulsky J, Ubel P, Schrag D, Nicolla J, Abernethy AP, Peppercorn J, Zafar SY. Patient-oncologist cost communication, financial distress, and medication adherence. J Oncol Pract. 2014 May; 10(3):162-7. PMID: 24839274; PMCID: PMC10445786.
      Citations: 101     Fields:    Translation:Humans
    Bestvina's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (123)
    Co-Authors (33)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors